Research ArticleParkinson’s Disease

LRRK2 activation in idiopathic Parkinson’s disease

See allHide authors and affiliations

Science Translational Medicine  25 Jul 2018:
Vol. 10, Issue 451, eaar5429
DOI: 10.1126/scitranslmed.aar5429

Article Information

vol. 10 no. 451

PubMed: 
Print ISSN: 
Online ISSN: 
History: 
  • Received for publication November 20, 2017
  • Accepted for publication March 22, 2018

Author Information

  1. Roberto Di Maio1,2,3,
  2. Eric K. Hoffman1,2,
  3. Emily M. Rocha1,2,
  4. Matthew T. Keeney1,2,
  5. Laurie H. Sanders1,2,4,
  6. Briana R. De Miranda1,2,
  7. Alevtina Zharikov1,2,
  8. Amber Van Laar1,2,
  9. Antonia F. Stepan5,
  10. Thomas A. Lanz5,
  11. Julia K. Kofler6,
  12. Edward A. Burton1,2,7,
  13. Dario R. Alessi8,
  14. Teresa G. Hastings1,2 and
  15. J. Timothy Greenamyre1,2,7,*
  1. 1Pittsburgh Institute for Neurodegenerative Diseases, University of Pittsburgh, Pittsburgh, PA 15213, USA.
  2. 2Department of Neurology, University of Pittsburgh, Pittsburgh, PA 15213, USA.
  3. 3Ri.MED Foundation, Palermo, Italy.
  4. 4Department of Neurology, Duke University, Durham, NC 27710, USA.
  5. 5Worldwide Medicinal Chemistry, Pfizer Worldwide Research and Development, Cambridge, MA 02139, USA.
  6. 6Department of Pathology, University of Pittsburgh, Pittsburgh, PA 15213, USA.
  7. 7Geriatric Research, Education and Clinical Center, VA Pittsburgh Healthcare System, Pittsburgh, PA 15240, USA.
  8. 8MRC Protein Phosphorylation and Ubiquitylation Units, University of Dundee, Dundee, Scotland.
  1. *Corresponding author. Email: jgreena{at}pitt.edu

Altmetric

Article usage

Article usage: July 2018 to September 2018

AbstractFullPdf
Jul 201875577551584
Aug 2018109819551171
Sep 2018331107104